Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

View 0 Studies Requested

Browse Lab Results > 2009-0562

Trial Summary

About CDAS Project, PI, Publications: Serum Estrogens and Subsequent Risk of Prostate Cancer

Datasets


Site: Prostate

Inclusion Criteria:

  • All I-Arm Men
  • No Prior History of Prostate Cancer
  • White, Non-Hispanic
  • Not From Hawaii Center
  • No Rare Cancers in Controls
  • Perfect Serum at T0 or .5+ ml child or in 2008-256,2009-555, or 2009-565
  • Incident (Cases Only)
  • In Prostate BPC3 Biochemical
  • In Final Population (Original Selection Line)
  • Has .5ml of Serum Available
  • Updated Advanced Case or Updated Control
  • Updated Case with Age at Dx <= 70 or Updated Control
  • Exclude All Rare Cancers
  • No Controls With no Results
  • Matched Cases at a 1-1 Ratio

Matching Factors:

  • Age at Randomization (5 year intervals)
  • Original Draw Year

Match Ratio: 1 to 1

Match Technique: Frequency matching only non-cases as controls.


Analytes:

  • 16-Epiestriol
  • 16-Ketoestradiol
  • 16Alpha-Hydroxyestrone
  • 17-Epiestriol
  • 2-Hydroxyestradiol
  • 2-Hydroxyestrone
  • 2-Hydroxyestrone-3-Methyl Ether
  • 2-Methoxyestradiol
  • 2-Methoxyestrone
  • 4-Hydroxyestrone
  • 4-Methoxyestradiol
  • 4-Methoxyestrone
  • Estradiol
  • Estriol
  • Estrone

Number of Cases: 195

Number of Controls: 195